Nirsevimab immunisation of infants and respiratory syncytial virus (RSV)-associated hospitalisations, Western Australia, 2024: a population-based analysis

Lauren E Bloomfield^{1

2}, Nevada V Pingault¹, Rachel E Foong¹, Sarah French¹, Jo-Anne Morgan¹, Ushma Wadia^{3

4}, Hannah C Moore^{4

5}, Christopher C Blyth^{4

6}, Peter C Richmond⁴, Paul K Armstrong¹, Paul V Effler^{1

6}

Affiliations

¹ Western Australia Department of Health, Perth, WA.
² University of Notre Dame Australia, Fremantle, WA.
³ Perth Children's Hospital, Perth, WA.
⁴ Wesfarmers Centre of Vaccine and Infectious Diseases, the Kids Research Institute Australia, Perth, WA.
⁵ Curtin University, Perth, WA.
⁶ University of Western Australia, Perth, WA.

Lauren E Bloomfield et al. Med J Aust. 2025.

. 2025 Jun 16;222(11):568-570.

doi: 10.5694/mja2.52655. Epub 2025 Apr 28.

¹ Western Australia Department of Health, Perth, WA.
² University of Notre Dame Australia, Fremantle, WA.
³ Perth Children's Hospital, Perth, WA.
⁴ Wesfarmers Centre of Vaccine and Infectious Diseases, the Kids Research Institute Australia, Perth, WA.
⁵ Curtin University, Perth, WA.
⁶ University of Western Australia, Perth, WA.

No abstract available

Keywords: Respiratory tract infections; Vaccination; Vaccine preventable disease.

Conflict of interest statement

No relevant disclosures.

1. Li Y, Wang X, Blau DM, et al; Respiratory Virus Global Epidemiology Network; RESCEU investigators . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022; 399: 2047‐2064. - PMC - PubMed
1. Evohealth . Time to act: protecting our children from RSV. May 2023. https://www.evohealth.com.au/wp‐content/uploads/2023/09/Time‐to‐Act‐prot... (viewed Mar 2025).
1. Hammitt LL, Dagan R, Yuan Y, et al; MELODY Study Group . Nirsevimab for prevention of RSV in healthy late‐preterm and term infants. N Engl J Med 2022; 386: 837‐846. - PubMed
1. Muller WJ, Madhi SA, Seoane Nuñez B, et al. MELODY Study Group. Nirsevimab for prevention of RSV in term and late‐preterm infants. N Engl J Med 2023; 388: 1533‐1534. - PubMed
1. Therapeutic Goods Administration . Australian product information Beyfortus™ (nirsevimab) solution for injection. 24 Nov 2024. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&... (viewed Jan 2025).